Immunogen: Most antibodies (e.g., 66550-1-Ig, 16290-1-AP) use recombinant ARC fusion proteins for high specificity .
Cross-Reactivity: Mouse and rabbit antibodies show broad reactivity across mammals (human, mouse, rat) but not Drosophila Arc1 unless explicitly tested .
Storage: PBS with 0.02% sodium azide and 50% glycerol at -20°C ensures long-term stability .
ARC1 regulates synaptic plasticity by modulating AMPA receptor trafficking and dendritic spine morphology . Antibodies like 16290-1-AP have been used to detect ARC1 in brain tissues, revealing its activity-dependent expression in dendritic spines .
In Drosophila, Arc1 (homologous to mammalian ARC) forms retrovirus-like capsids for mRNA transport between neurons and muscles, a process validated using immunostaining .
ARC1 antibodies (e.g., 66550-1-Ig) identified Arc1 as a fat storage regulator in Drosophila larvae. Null mutants showed increased body fat, while overexpression reduced lipid accumulation .
ARC1 interacts with microbiota to modulate growth and metabolism. Germ-free Drosophila lacking Arc1 exhibit stunted growth, reversible by Acetobacter colonization .
ARC1 dysfunction is linked to autism, schizophrenia, and Alzheimer’s disease. Antibodies like #94147 detect ARC in human brain tissues, where it suppresses apoptosis and necroptosis in cancer cells .
Mammalian ARC antibodies (e.g., 66550-1-Ig) do not cross-react with Drosophila Arc1 due to sequence divergence. Studies on Drosophila require species-specific tools .
Human/mouse-reactive antibodies (e.g., #38916) are optimized for detecting post-translational modifications like Thr149 phosphorylation, critical for mitochondrial targeting .
KEGG: sce:YGL105W
STRING: 4932.YGL105W
ARC1 is a conserved activity-regulated immediate early gene product that plays crucial roles beyond memory and learning. Research has revealed that ARC1 is involved in neuronal regulation of organismal metabolism, particularly in fat storage regulation . Unlike other immediate early genes such as jra and kay (fly orthologs of jun and c-fos), ARC1 shows stronger induction in response to neuronal activity, suggesting more specific effector roles .
The protein functions in both pre- and postsynaptic compartments and has been observed in multivesicular body-like structures (MVBLS) and extracellular vesicles (EVs) in the synaptic cleft of glutamatergic synapses . Recent evidence also supports inter-neuronal in vivo transfer of Arc in the mammalian brain .
ARC1 shows distinct expression patterns across brain regions, with quantitative differences that can be visualized through western blotting and immunohistochemistry.
In Drosophila studies, ARC1 expression has been observed in specific clusters of cells that respond to neuronal activity, with differential expression patterns in the ventral nerve cord (VNC) and subesophageal ganglion (SOG) .
Antibody specificity is critical for reliable research results. The polyclonal rabbit Arc antibody from Synaptic Systems (Cat#156003, RRID: AB_887694) has been verified for specificity through:
Immunocytochemistry of dissociated hippocampal neuron cultures prepared from wild type (WT) and Arc knockout (KO) littermates
Western blotting, which should show a single immunoreactive band at the expected molecular weight
For your own validation, consider these approaches:
Compare staining in wild-type tissues with Arc knockout tissues
Perform western blotting to confirm a single band at the appropriate molecular weight
Include appropriate negative controls in all experiments
Verify consistency of staining patterns with previously published results
For reliable ARC1 immunostaining in neural tissue, the following protocol has been successfully employed:
Dissect tissue (e.g., wandering 3rd instar larvae for Drosophila studies)
Fix with 4% paraformaldehyde overnight at 4°C
Wash three times with 0.1% PBTriton
For primary antibody dilution, researchers have successfully used:
1:400 dilution for electron microscopy
1:500 dilution for light microscopy
ARC1 expression is dynamically regulated by neuronal activity, with specific functional consequences. In Drosophila studies, manipulation of E347 neuronal activity revealed that:
Stimulation of E347 neurons significantly increased ARC1-positive cells in the ventral nerve cord (VNC)
Silencing E347 neurons significantly decreased ARC1-positive cells in the VNC and subesophageal ganglion (SOG)
Interestingly, silencing E347 neurons increased ARC1-positive peripheral lobe cells
These region-specific changes in ARC1 expression correlate with metabolic regulation. Arc1 null mutants show increased body fat, decreased density consistent with increased fat storage, and significant metabolic alterations including:
Higher levels of glycogen breakdown products
Inefficient glucose oxidation through glycolysis and Krebs cycle
Accumulation of carbon backbone for de novo synthesis of triglycerides
~330-fold reduction in transcripts encoding PEPCK
Highest statistically significant fold-change increase in aspartate
To visualize ARC1 dynamics in living neurons, researchers have successfully employed CRISPR/Cas9 homology-independent targeted integration (HITI) for knock-in of fluorescent markers. Key methodological considerations include:
Construction of an adeno-associated virus (AAV) system delivering:
Cas9
Reporter gene (mCherry or GFP)
Single guide RNA (sgRNA)
Targeting of genomic sites surrounding the start codon of the ARC open reading frame
Viral injection into target brain regions (e.g., striatum and hippocampus)
Visualization through immunohistochemistry and proximity ligation assay (PLA)
This approach allows production of a chimeric functional ARC protein in a sparse population of transduced neurons, facilitating in vivo synapse and cell-to-cell communication studies of ARC in the intact brain .
Distinguishing between pre- and postsynaptic ARC1 localization requires high-resolution imaging techniques. Electron microscopy studies have revealed:
ARC-immunopositive multivesicular body-like structures (MVBLS)
ARC presence in both presynaptic and postsynaptic cytoplasm
ARC-immunopositive extracellular vesicles (EVs) in the synaptic cleft of glutamatergic synapses
For accurate differentiation, consider:
Using electron microscopy with immunogold labeling
Employing co-localization studies with established pre- and postsynaptic markers
Utilizing super-resolution microscopy techniques (STED, STORM, or PALM)
Combining with electrophysiological recordings to correlate localization with function
Accurate quantification of ARC1-positive cells requires careful methodological approaches:
Perform immunostaining with validated antibodies (e.g., 1:500 dilution for light microscopy)
Collect images using a confocal microscope for optimal resolution
Conduct cell counts blind to experimental condition to prevent bias
Use appropriate statistical tests (e.g., Multiple t-test comparison for comparing cell counts between conditions)
When analyzing changes in ARC1 expression:
Count the number of clearly ARC1-positive cells in different regions of the brain under different conditions
Be aware that immunostaining may not be sensitive enough to detect changes in protein content per cell
Consider complementing cell counting with RT-qPCR or RNAseq for mRNA quantification
Recent evidence supports inter-neuronal transfer of ARC in the mammalian brain . To investigate this phenomenon:
Use CRISPR/Cas9 HITI to knock-in fluorescent markers (e.g., GFP or mCherry) to the ARC protein
This allows visualization of ARC protein dynamics in sparse populations of neurons
Examine the presence of labeled ARC in non-transduced neurons, which would indicate inter-neuronal transfer
Combine with electron microscopy to visualize ARC-containing extracellular vesicles in the synaptic cleft
For functional studies, consider:
Selectively manipulating ARC expression in specific neuronal populations
Examining the effects on neighboring cells' physiology and gene expression
Using microfluidic chambers to separate neuronal populations while allowing process interaction
For reliable quantification of ARC1 mRNA expression by RT-qPCR, researchers have successfully used the following primer pairs:
| Target | Primer Pair | Sequence |
|---|---|---|
| Arc1 | Pair 1 | Forward: 5′ catcatcgagcacaacaacc 3′ Reverse: 5′ ctactcctcgtgctgctcct 3′ |
| Arc1 | Pair 2 | Forward: 5′ tcggtctgctgaacatcaag 3′ Reverse: 5′ gtgttctttgctgtggcaag 3′ |
For normalization, consider housekeeping genes used in previous studies:
actin5c: Forward 5′ gagcgcggttactctttcac 3′, Reverse 5′ acttctccaacgaggagctg 3′
alpha-tubulin84B: Forward 5′ aacctgaaccgtctgattgg 3′, Reverse 5′ ggtcaccagagggaagtgaa 3′
When performing RT-qPCR:
Include at least three independent biological replicates
Use multiple comparisons ordinary one-way ANOVA to calculate statistical significance
Consider comparing ARC1 expression with other immediate early genes (e.g., jra and kay) to assess specificity of responses
Variable immunostaining results can stem from several factors:
ARC1 expression is activity-dependent and can vary based on neuronal stimulation state
Expression patterns differ significantly across brain regions, with highest expression in cortex and hippocampus
Different fixation protocols may affect antibody accessibility to epitopes
ARC1 expression can change rapidly in response to experimental manipulations
To improve consistency:
Standardize tissue collection and preparation protocols
Control for time of day and animal activity levels before tissue collection
Ensure consistent fixation times and temperatures
Process all experimental groups in parallel
Include positive and negative controls in each experiment
Detecting subtle changes in ARC1 expression requires careful experimental design:
ARC1's involvement in metabolic regulation presents intriguing therapeutic possibilities:
ARC1 null mutants show increased body fat and significant metabolic alterations, suggesting potential targets for obesity interventions
Key metabolic changes in ARC1 mutants include:
Future research could explore:
Pharmacological modulation of ARC1 expression or function to influence metabolic outcomes
Cell-specific targeting of ARC1 in metabolically relevant neural circuits
Interaction between ARC1 and other metabolic regulators, such as insulin signaling pathways
Translational potential of ARC1-targeted approaches for metabolic disorders
Emerging technologies hold promise for advancing our understanding of ARC1 dynamics:
CRISPR/Cas9 HITI for fluorescent tagging of endogenous ARC1 enables visualization of the protein in living neurons
Super-resolution microscopy techniques could provide more detailed visualization of ARC1 localization at synapses
Optogenetic approaches combined with ARC1 visualization could help elucidate activity-dependent regulation
Single-cell transcriptomics could reveal cell-specific responses in ARC1 expression
Future technical developments might include:
Photoactivatable or photoconvertible ARC1 fusion proteins to track protein movement between cells
Genetically encoded indicators that report on ARC1 activity or interaction with binding partners
Cryo-electron microscopy to determine ARC1 structure and interaction with multivesicular bodies and extracellular vesicles
AI-assisted image analysis for high-throughput quantification of ARC1 dynamics across large datasets